v3.26.1
Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost - UCB Pharma S.A. - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Collaborative arrangements and non-collaborative arrangement transactions        
Expense incurred by the collaboration $ 29.3 $ 17.8 $ 58.7 $ 39.6
Expense reflected within statements of income $ 14.6 $ 8.9 $ 29.3 $ 19.8